Letter to Editor: Light mask trial response

Article

With reference to the Ophthalmology Times article titled "Light mask ineffective for diabetic macular oedema" published on 31st August, I am writing to make you aware of our grave concerns over the analysis and reporting of the CLEOPATRA study as we believe it presents a wholly false and inaccurate summary of the trial and the results.

The focus of our concern can be summarised as follows If a patient does not take a treatment they cannot derive any benefit: Only 4.5% of patients (7/155) enrolled into the trial consistently achieved or exceeded the compliance target.

There are 4 main areas identified within the published CLEOPATRA paper that are of major importance which are discussed in more detail in detail in the attached paper.
1. Questionable statistical model used for analysis – median percentage;
2. Very low mask usage/compliance; Only 4.5% of patients (7/155) enrolled into the trial consistently achieved or exceeded the compliance target
3. Patient management, communication and feedback processes;
4. Questionable interpretation of 12 month diffuse DMO benefit which was unsustained at 24 months.

On a positive note, the CLEOPATRA study did confirm that the light therapy is safe and also reported another key finding - that half way through the trial the light-masks significantly reduced diffuse diabetic macular oedema. The authors went on to note that this improvement seen at the 12 month mark, was not sustained at 24 months, concluding that the effect was transient and minimal. This was interpreted as a loss of efficacy of the intervention over time, but the analysis did not take into account that, compared with the first year, there was a significant drop in compliance during the second year potentially explaining the transient nature of the effect.

PolyPhotonix has repeatedly requested further post-hoc analysis, where an appropriate statistical model is used to analyse the effect of mask usage patterns.

PolyPhotonix has also submitted a correspondence letter to The Lancet and our full rebuttal document is available for your information.

 

-Moira Hopkins | Commercial Portfolio Manager, PolyPhotonix

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
Related Content
© 2025 MJH Life Sciences

All rights reserved.